{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T15:29:13Z","timestamp":1794410953341,"version":"4.9.0"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To determine the efficacy of intravitreal ranibizumab (IVR) treatment for advanced familial exudative vitreoretinopathy with high vascular activity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The retrospective interventional case series included 28 eyes (20 patients) that had IVR in combination or not with other treatment, for Stage 3 to 5 familial exudative vitreoretinopathy with active fibrovascular proliferation and prominent subretinal exudation. Outcome measures were fundus features after treatment, associated clinical variables, and genetic mutations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The age of patients at the first IVR ranged from 0.2 to 36 months. An average of 1.3 IVR injections per eye were given. Familial exudative vitreoretinopathy regressed in 16 (57%) eyes and progressed in 12 eyes (43%) after IVR. Laser and\/or vitrectomy was performed on 13 eyes. The retina was reattached in 22 eyes (78%) after 24 to 58 months follow-up. Clinical variables associated with progression after IVR were preexisting fibrovascular proliferation over one quadrant and persistent vascular activity after the initial injection (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.05). Familial exudative vitreoretinopathy-causative genetic mutations in 11 patients were related to variable response to IVR treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Intravitreal ranibizumab treatment may effectively regress advanced familial exudative vitreoretinopathy with high vascular activity in selected cases. Different treatment outcomes may be relevant to variable presentation and genetic heterogeneity of familial exudative vitreoretinopathy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/iae.0000000000003122","type":"journal-article","created":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T07:57:19Z","timestamp":1611907039000},"page":"1976-1985","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["INTRAVITREAL RANIBIZUMAB TREATMENT FOR ADVANCED FAMILIAL EXUDATIVE VITREORETINOPATHY WITH HIGH VASCULAR ACTIVITY"],"prefix":"10.1097","volume":"41","author":[{"given":"Jiao","family":"Lyu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Fei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiquan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250609","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/S0161-6420(84)34119-7","article-title":"Retinal vascular pattern in familial exudative vitreoretinopathy","volume":"91","author":"Miyakubo","year":"1984","journal-title":"Ophthalmology"},{"key":"R2-20250609","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1001\/archopht.1971.01000010152007","article-title":"Familial exudative vitreoretinopathy. An expanded view","volume":"86","author":"Gow","year":"1971","journal-title":"Arch Ophthalmol"},{"key":"R3-20250609","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.preteyeres.2018.11.008","article-title":"Wnt Signaling in vascular eye diseases","volume":"70","author":"Wang","year":"2019","journal-title":"Prog Retin Eye Res"},{"key":"R4-20250609","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1001\/jamaophthalmol.2014.2814","article-title":"Phenotypic overlap between familial exudative vitreoretinopathy and microcephaly, lymphedema, and chorioretinal dysplasia caused by KIF11 mutations","volume":"132","author":"Robitaille","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"R5-20250609","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/humu.21250","article-title":"Overview of the mutation spectrum in familial exudative vitreoretinopathy and Norrie disease with identification of 21 novel variants in FZD4, LRP5, and NDP","volume":"31","author":"Nikopoulos","year":"2010","journal-title":"Hum Mutat"},{"key":"R6-20250609","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0092-8674(04)00216-8","article-title":"Vascular development in the retina and inner ear: control by Norrin and Frizzled-4, a high-affinity ligand-receptor pair","volume":"116","author":"Xu","year":"2004","journal-title":"Cell"},{"key":"R7-20250609","doi-asserted-by":"crossref","first-page":"9856","DOI":"10.1073\/pnas.1220864110","article-title":"ZNF408 is mutated in familial exudative vitreoretinopathy and is crucial for the development of zebrafish retinal vasculature","volume":"110","author":"Collin","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R8-20250609","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/S0161-6420(98)96002-X","article-title":"Familial exudative vitreoretinopathy. Results of surgical management","volume":"105","author":"Pendergast","year":"1998","journal-title":"Ophthalmology"},{"key":"R9-20250609","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1016\/j.ophtha.2014.05.029","article-title":"Diversity of retinal vascular anomalies in patients with familial exudative vitreoretinopathy","volume":"121","author":"Kashani","year":"2014","journal-title":"Ophthalmology"},{"key":"R10-20250609","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ajo.2011.06.002","article-title":"Clinical features of congenital retinal folds","volume":"153","author":"Nishina","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"R11-20250609","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.ophtha.2015.09.010","article-title":"Structure and morphology of radial retinal folds with familial exudative vitreoretinopathy","volume":"123","author":"Katagiri","year":"2016","journal-title":"Ophthalmology"},{"key":"R12-20250609","doi-asserted-by":"crossref","first-page":"8614","DOI":"10.1167\/iovs.14-15693","article-title":"The role of the hypoxia response in shaping retinal vascular development in the absence of Norrin\/Frizzled4 signaling","volume":"55","author":"Rattner","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R13-20250609","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1097\/IAE.0b013e3181679bf6","article-title":"Treatment of vascularly active familial exudative vitreoretinopathy with pegaptanib sodium (Macugen)","volume":"28","author":"Quiram","year":"2008","journal-title":"Retina"},{"key":"R14-20250609","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N Engl J Med"},{"key":"R15-20250609","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.jaapos.2015.09.006","article-title":"Long-term follow-up of intravitreal bevacizumab for the treatment of pediatric retinal and choroidal diseases","volume":"19","author":"Henry","year":"2015","journal-title":"J AAPOS"},{"key":"R16-20250609","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/j.ophtha.2017.03.018","article-title":"Ranibizumab injection as primary treatment in patients with retinopathy of prematurity: anatomic outcomes and influencing factors","volume":"124","author":"Huang","year":"2017","journal-title":"Ophthalmology"},{"key":"R17-20250609","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.ajo.2014.08.009","article-title":"Surgical outcomes of progressive tractional retinal detachment associated with familial exudative vitreoretinopathy","volume":"158","author":"Yamane","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"R18-20250609","doi-asserted-by":"crossref","first-page":"5368","DOI":"10.1167\/iovs.17-23541","article-title":"Spectrum of variants in 389 Chinese probands with familial exudative vitreoretinopathy","volume":"59","author":"Li","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R19-20250609","doi-asserted-by":"crossref","first-page":"26564","DOI":"10.1038\/srep26564","article-title":"Identification of novel KIF11 mutations in patients with familial exudative vitreoretinopathy and a phenotypic analysis","volume":"6","author":"Li","year":"2016","journal-title":"Sci Rep"},{"key":"R20-20250609","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3928\/23258160-20190129-10","article-title":"A novel pathogenic variant in NDP gene with incomplete penetrance manifests as X-linked familial exudative vitreoretinopathy","volume":"50","author":"Scott","year":"2019","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"R21-20250609","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1167\/iovs.16-21324","article-title":"Mutations in LRP5,FZD4, TSPAN12, NDP, ZNF408, or KIF11 genes account for 38.7% of Chinese patients with familial exudative vitreoretinopathy","volume":"58","author":"Rao","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R22-20250609","first-page":"395","article-title":"Identification of two novel LRP5 mutations in families with familial exudative vitreoretinopathy","volume":"20","author":"Fei","year":"2014","journal-title":"Mol Vis"},{"key":"R23-20250609","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1136\/bjophthalmol-2016-309526","article-title":"Anatomical and functional outcomes following vitrectomy for advanced familial exudative vitreoretinopathy: a single surgeon's experience","volume":"101","author":"Hocaoglu","year":"2017","journal-title":"Br J Ophthalmol"},{"key":"R24-20250609","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1097\/IAE.0000000000001725","article-title":"Retinal detachment surgery in A pediatric population: visual and anatomic outcomes","volume":"38","author":"Read","year":"2018","journal-title":"Retina"},{"key":"R25-20250609","doi-asserted-by":"crossref","first-page":"107720","DOI":"10.1016\/j.exer.2019.107720","article-title":"Symmetry of folds in FEVR: a genotype-phenotype correlation study","volume":"186","author":"Wang","year":"2019","journal-title":"Exp Eye Res"},{"key":"R26-20250609","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1001\/archophthalmol.2009.35","article-title":"Lens-sparing vitrectomy effective for reattachment of newly developed falciform retinal detachment in a patient with Norrie disease","volume":"127","author":"Shima","year":"2009","journal-title":"Arch Ophthalmol"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000003122","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T12:01:22Z","timestamp":1749470482000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000003122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000003122","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]}}}